Lack of association of the HMGA1 gene variants with insulin resistance risk development in the Iraqi population: Case-control study

Main Article Content

Mirna Kifah Faiq
Eman Saadi Saleh
Omar Basher Fathalla

Keywords

HMGA1 gene; insulin resistance, Iraqi population; metabolic syndrome; diabetes mellitus

Abstract

Reduced sensitivity or responsiveness to the metabolic effects of insulin is the typical definition of insulin resistance. High mobility group A1 (HMGA1) can enhance the body's capacity to store fat and improve insulin sensitivity, so the abnormal decrease in HMGA1 or its variants may be related to type 2 diabetes and poor adipocyte differentiation, which results in insulin resistance. The goal of this study was to examine whether HMGA1 genetic variants in a sample of the Iraqi population can predict the risk of an increase in insulin resistance. This case-control study was carried out at a single center in Kirkuk, Iraq, from February to August 2022. This study included 30 healthy Iraqi participants and 30 patients without diabetes who had metabolic syndrome. Sanger sequencing of genomic DNA was used to identify HMGA1 polymorphisms and genotypes. The high prevalence of CC and GG genotypes of rs1023028442 and rs112081775 respectively was seen in the Iraqi population. Minor allele frequency of rs1023028442 was higher among metabolic patients without diabetes with (MAF=0.08) compared to the control group with (MAF= 0%). While (MAF=0.1) of rs112081775 was seen in metabolic patients without diabetes compared to (MAF=0.02) in the control group. After adjusting age, gender, and BMI as covariates, linear regression analysis showed no significant effect of these two variants (C>T, and G>A) on developing insulin resistance. Thus, the rs1023028442 with C>T genotype and rs112081775 with G>A genotype in the HMGA1 gene did not predict the risk of an increase in insulin resistance in the Iraqi populations.

Abstract 215 | pdf Downloads 98

References

1. Fakree NK, Ali SH: Effect of COX-2 Inhibitors Selectivity on Lipid Profile in Hyperlipidemic and Normolipidemic Type 2 Diabetics. Iraqi J.
Pharm. Sci. 2009; 18(Suppl): 7–13.
2. Mikhael EM, Hassali MA, Hussain SA, Shawky N. Self-management knowledge and practice of type 2 diabetes mellitus patients in Baghdad, Iraq: a qualitative study. Diabetes Metab Syndr Obes. 2018;12:1-17.
3. Kojta I, Chacińska M, Błachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. Nutrients.
2020;12(5):1305.
4. Fahed G, Aoun L, Bou Zerdan M, Allam S, Bouzerdan M, Bouferraa Y. et al. Metabolic Syndrome: Updates on Pathophysiology and
Management in 2021. Int J Mol Sci. 2022;23(2):786.
5. Singh Y, Garg MK, Tandon N, Marwaha RK. A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in
urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013;5(4):245-251.
6. Gayoso-Diz P, Otero-González A, RodriguezAlvarez MX, Gude F, Garcỉa F, De Francisco A, et al. Insulin resistance (HOMA-IR) cut-off
values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr
Disord. 2013;13:47.
7. Kadhim DJ, Kadhim SA, Ali FZ, Fawzi HA. Prevalence of Depression among Mothers of Children with Type 1 Diabetes Mellitus
attending two Diabetes Centers. Indian Journal of Public Health Research and Development.2019;10: 448-454.
8. Pujals M, Resar L, Villanueva J. HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!.
Biomolecules. 2021;11(9):1334.
9. Vignali R, Marracci S. HMGA Genes and Proteins in Development and Evolution. Int J Mol Sci. 2020;21(2):654.
10. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020;21(17):6275.
11. Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011;32(4):498-514.
12. Kong H, Liu Y, Zheng L, Wang Q, Zhang Y. One of the Crucial Proteins to Influence Type 2 Diabetes: The High Mobility Group A1.
Biosc.Biotech.Res.Comm. 2016;9(4):580-586.
13. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5-6):231-237. doi:10.1242/dmm.001180.
14. Sahu, Suchanda. . Calculation of VLDLcholesterol from triglycerides and total cholesterol levels. Biomedicine. 2008;28. 219-221.
15. World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human
subjects.Bulletin of the World Health Organization. 2001;79 (4), 373 - 374.
16. Hussein EA, Kadhim DJ, Al-Auqbi TF. Belief about medications among type 2 diabetic patients attending the National Diabetes Center in Iraq. Iraqi J Pharm Sci. 2017;26(2):66–74.
17. Regufe VMG, Pinto CMCB, Perez PMVHC. Metabolic syndrome in type 2 diabetic patients: a review of current evidence. Porto Biomed J.
2020;5(6):e101.
18. Chiefari E, Foti DP, Sgarra R, Pegoraro S, Arcidiacono B, Brunetti FS, et al. Transcriptional Regulation of Glucose Metabolism: The
Emerging Role of the HMGA1 Chromatin Factor. Front Endocrinol (Lausanne). 2018;9:357.
19. Chiefari E, Tanyolaç S, Paonessa F, Pullinger CR, Capula C, Iritano S, et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA. 2011;305(9):903-912.
20. Liu L, Ding H, Wang HR, Xu YJ, Cui GL, Wang PH, et al. Polymorphism of HMGA1 is associated with increased risk of type 2 diabetes among
Chinese individuals. Diabetologia. 2012;55(6):1685-1688.
21. Rigau M, Juan D, Valencia A, Rico D. Intronic CNVs and gene expression variation in human populations. PLoS Genet. 2019;15(1):e1007902.
22. Lin H, Hargreaves KA, Li R, Reiter JL. Wang Y. Mort M. et al. RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants. Genome Biol. 2019;20(1):254.
23. Marquez M, Huyvaert M, Perry JR, Pearson RD, Falchi M, Morris AP, et al. Low-frequency variants in HMGA1 are not associated with type 2 diabetes risk. Diabetes. 2012;61(2):524-530.
24. Chiefari E, Tanyolaç S, Iiritano S, Sciacqua A, Capula C, Arcidiacono B, et al. A polymorphism of HMGA1 is associated with increased risk of
metabolic syndrome and related components. Sci Rep. 2013;3:1491.